Not exact matches
Certain matters discussed in this news release are forward - looking statements that involve a number
of risks and uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and
introduction, customer acceptance
of new products, the impact
of competitive products and pricing, market acceptance, the lengthy sales
cycle, proprietary rights
of the Company and its competitors, risk
of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for
new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant
cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the
introduction of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit
new drug applications for
new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for
new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop
new products and services in a timely manner or at competitive prices, including risks related to
new product
introductions; risks related to BlackBerry's ability to mitigate the impact
of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact
of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits
of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure
of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers
of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice
of providing forward - looking guidance; potential charges relating to the impairment
of intangible assets recorded on BlackBerry's balance sheet; risks as a result
of actions
of activist shareholders; government regulation
of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life
cycles that characterize the wireless communications industry.
The one game that broke the vicious Sonic
Cycle was Sonic Colors, thanks to the
introduction of Wisp power - ups, a
new voice cast (save for the charming and incomparable Mike Pollock as Doctor Eggman), candy - eyed graphics, and gorgeous level design.
Independent Practice is the part
of the lesson
cycle where students are given the opportunity to practice the concept presented during the
Introduction to
New Learning and is a time for students to work towards mastery
of the knowledge / skills presented in the lesson before an assessment is given.
Branding exercise aside, a strategy revision is likely
of more interest to German hot - rod enthusiasts: Where RS models during the past decade - plus tended to arrive at the tail end
of a given car's life
cycle — and even skip certain generations
of those cars — they will now arrive within the first year or two
of a
new model's
introduction, and RS badging will be present on 10 different vehicles by the end
of 2018, with the
new RS5 up next at the beginning
of the year.
You can learn a lot during the paper writing process, and might see us incorporate many useful techniques, such as: analysing other essays on the topic that were well - written, defining an intelligent and impactful thesis statement, crafting the main body
of the essay (with flexibility, allowing it to adapt to changing ideas as
new research or concepts are discovered), producing an intriguing title and
introduction (these are usually best left for the end
of the drafting
cycle), and lastly, formulating a conclusion that best summarises the entire body
of work.
Console sales have far outpaced previous
new introductions, and the timing
of the peak
of the
cycle is still uncertain.
By using this image, the
cycle questions the
new dynamics between a work
of art and its
introduction to the world, ultra-connected and swamped with images.
Water
cycle carbon
cycle human impacts stores processes climate change weather pollution flooding sustainable water supply water and carbon control at global scale To support teachers with the
introduction of the 2016 A Level courses, the Society is providing a
new range
of online resources and support.
Summary
of Qualifications * PMI - PMP certified Project management and Product development specialist *
New Product
Introduction / Concept to Launch / Project Life
cycle management * Bachelors in Mechanical Engineering with overall 11 + years
of industrial experience including project / program management, project co-ordination, stakeholder engagement, vendor / contractor management, supply chain development, customer site vis...
«A
new potential threat to stability in this development
cycle is the
introduction of apartment REITs into the supply vs. demand equation.